Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study Meeting Abstract
| Authors: | Cohen, J. B.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Cheah, C. Y.; Eyre, T. A.; Ujjani, C. S.; Koh, Y.; Kim, W. S.; Nasta, S. D.; Flinn, I. W.; Tessoulin, B.; Ma, S.; Alencar, A. J.; Lewis, D.; Woyach, J. A.; Maddocks, K. J.; Patel, K.; Wang, Y.; Rhodes, J. M.; Tam, C. S.; Seymour, J. F.; Nagai, H.; Vose, J. M.; Fakhri, B.; Hoffmann, M. S.; Hernandez-Ilizaliturri, F. J.; Zelenetz, A. D.; Kumar, A.; Munir, T.; Tsai, D. E.; Balbas, M.; Liu, B.; Ruppert, A. S.; Nguyen, B.; Roeker, L. E.; Wang, M. L. |
| Abstract Title: | Pirtobrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients with prior cBTKi: Safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 981 |
| Language: | English |
| ACCESSION: | WOS:001159306704005 |
| DOI: | 10.1182/blood-2023-181627 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work